抗感染症薬 - 世界市場の考察、競合情勢、市場予測（2030年）

世界の抗感染症薬の市場規模は1,368億7,000万米ドルに達しており、2030年までに1,759億4,000万米ドルに達し、2024年～2030年の予測期間にCAGRで4.38%の成長が見込まれます。市場は、世界中でHIV、敗血症、結核、院内感染、性感染症などの感染症や標的疾患の有病率が増加していることから、大幅な市場成長を示しています。さらに、感染症に対する意識の高まりや、標的疾患や感染症に罹患しやすい老年人口の増加も、抗感染症薬の需要の増加を後押ししています。さらに、細胞が人体で経験する自然な生理機能や機械的な力を再現するために生体機能チップ技術を取り入れるなどの進歩が、結果として薬剤の効率を向上させ、抗感染症薬市場に拍車をかける見込みです。同様に、研究開発活動の活発化、医薬品の承認および上市の急増などの要因が、市場における抗感染症薬への要求を生み出します。したがって、市場は2024年～2030年の予測期間に大幅なCAGRで成長すると推定されます。

抗感染症薬の市場力学

世界保健機関（WHO）（2022）のデータによると、2022年に世界で推定1,060万人が結核に罹患し、その内訳は男性600万人、女性340万人、子供120万人です。さまざまな感染症が流行していることから、2022年～2028年の予測期間に抗感染症薬の需要が増加する見込みです。

さらに、世界のいくつかの地域では多剤耐性菌が大幅に増加しており、抗感染症薬の技術革新の重要性が強調されています。複数の機関が、感染症に対する社会の意識を高めるための取り組みやキャンペーンを開始しています。例えば、WHOは2022年11月に「Spread Awareness, Stop Resistance」をテーマにWorld Antimicrobial Awareness Week（WAAW）を開催し、抗菌薬耐性とその治癒についての認識を高めました。

さらに、薬剤の上市と承認の増加も、市場における抗感染症薬の需要を促進します。例えば、2022年5月、Gilead Sciences, Inc.は米国食品医薬品局（FDA）が注射型のレナカパビルをHIV治療とHIV曝露前予防薬（PrEP）として評価するための同社のIND申請に対する臨床保留命令を解除したと発表しました。

また、日本では2022年7月、Rocheが抗感染症薬「ロナプリーブ」（カシリビマブ、イムデビマブ）について、厚生労働省より「軽度から中等度のCOVID-19の点滴静注療法」として承認を取得したと発表しています。

したがって、2024年～2030年の予測期間を通じて、上記の要因が総合的に抗感染症薬市場全体を牽引します。

しかし、抗感染症薬耐性の出現や、抗感染症薬に伴う副作用、厳格な規制当局の承認などが、抗感染症薬市場の成長にとっての課題となる可能性があります。

抗感染症薬市場は、SARS-CoV-2ウイルスやその他の感染症の蔓延を防ぐために抗感染症薬が使用されたことから、COVID-19パンデミックの時期にプラスの影響を受けました。しかし、ロックダウンの初期段階では、厳格なロックダウン規制と製造およびサプライチェーンの混乱により、市場は落ち込みに見舞われました。しかし、抗感染症薬の需要が高まるにつれ、市場の主要企業は製造を加速させました。多くの主要企業が抗感染症薬に関する戦略的決定、投資、研究開発活動に没頭し、抗感染症薬の需要の増加につながっています。さらに、2020年10月、米国食品医薬品局は、入院が必要なCOVID-19の治療薬として、成人と12歳以上の小児患者に使用する抗ウイルス薬Veklury（remdesivir）を承認しました。以後、COVID-19の蔓延を防ぐために抗感染症薬が広く使用されるようになり、抗感染症薬市場の成長に大きく寄与しました。

当レポートでは、世界の抗感染症薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 抗感染症薬市場レポートのイントロダクション

第2章 抗感染症薬市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

第4章 抗感染症薬市場の主な要因の分析

• 抗感染症薬市場の促進要因
• 抗感染症薬市場の抑制要因と課題
• 抗感染症薬市場の機会

第5章 抗感染症薬市場のポーターのファイブフォース分析

第6章 抗感染症薬市場に対するCOVID-19の影響分析

第7章 抗感染症薬市場のレイアウト

• タイプ別
  • 抗生剤
  • 抗ウイルス薬
  • 抗真菌薬
  • その他
• 適応症別
  • HIV感染症
  • 肺炎
  • 呼吸器ウイルス感染症
  • 敗血症
• 投与経路別
  • 経口
  • 非経口
  • 局所
• 流通チャネル別
  • 病院薬局
  • 小売薬局
  • eコマース
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 抗感染症薬市場の企業と製品のプロファイル

• Merck & Co., Inc.
• Gilead Sciences, Inc.
• GSK plc.
• Pfizer Inc.
• Alembic Pharmaceuticals
• Mankind Pharma
• Novartis AG
• Abbott.
• Astellas Pharma d.o.o.
• Bayer AG
• Bristol-Myers Squibb Company
• Sanofi
• Janssen Global Services, LLC
• F. Hoffmann-La Roche Ltd
• Cipla Inc.
• Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
• Xellia Pharmaceuticals
• AbbVie Inc.
• Melinta Therapeutics LLC
• PACIFIC INDIA PHARMA LIMITED

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Anti-Infective Drugs Market
• Table 3: Anti-Infective Drugs Market Analysis in Global (2021-2030)
• Table 4: Anti-Infective Drugs Market Analysis in Global by Type (2021-2030)
• Table 5: Anti-Infective Drugs Market Analysis in Global by Indication (2021-2030)
• Table 6: Anti-Infective Drugs Market Analysis in Global by Route of Administration (2021-2030)
• Table 7: Anti-Infective Drugs Market Analysis in Global by Distribution Channel (2021-2030)
• Table 8: Anti-Infective Drugs Market Analysis in Global by Geography (2021-2030)
• Table 9: Anti-Infective Drugs Market Analysis in North America (2021-2030)
• Table 10: Anti-Infective Drugs Market Analysis in North America by Country (2021-2030)
• Table 11: Anti-Infective Drugs Market Analysis in the US (2021-2030)
• Table 12: Anti-Infective Drugs Market Analysis in Canada (2021-2030)
• Table 13: Anti-Infective Drugs Market Analysis in Mexico (2021-2030)
• Table 14: Anti-Infective Drugs Market Analysis in Europe (2021-2030)
• Table 15: Anti-Infective Drugs Market Analysis in Europe by Country (2021-2030)
• Table 16: Anti-Infective Drugs Market Analysis in France (2021-2030)
• Table 17: Anti-Infective Drugs Market Analysis in Germany (2021-2030)
• Table 18: Anti-Infective Drugs Market Analysis in the UK (2021-2030)
• Table 19: Anti-Infective Drugs Market Analysis in Italy (2021-2030)
• Table 20: Anti-Infective Drugs Market Analysis in Spain (2021-2030)
• Table 21: Anti-Infective Drugs Market Analysis in the Rest of Europe (2021-2030)
• Table 22: Anti-Infective Drugs Market Analysis in Asia-Pacific (2021-2030)
• Table 23: Anti-Infective Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 24: Anti-Infective Drugs Market Analysis in China (2021-2030)
• Table 25: Anti-Infective Drugs Market Analysis in Japan (2021-2030)
• Table 26: Anti-Infective Drugs Market Analysis in India (2021-2030)
• Table 27: Anti-Infective Drugs Market Analysis in Australia (2021-2030)
• Table 28: Anti-Infective Drugs Market Analysis in South Korea (2021-2030)
• Table 29: Anti-Infective Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 30: Anti-Infective Drugs Market Analysis in the Rest of the World (2021-2030)
• Table 31: Anti-Infective Drugs Market Analysis in the Rest of the World by Region (2021-2030)
• Table 32: Anti-Infective Drugs Market Analysis in the Middle East (2021-2030)
• Table 33: Anti-Infective Drugs Market Analysis in Africa (2021-2030)
• Table 34: Anti-Infective Drugs Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Anti-Infective Drugs Market
• Figure 3: Anti-Infective Drugs Market Analysis in Global (2021-2030)
• Figure 4: Anti-Infective Drugs Market Analysis in Global by Type (2021-2030)
• Figure 5: Anti-Infective Drugs Market Analysis in Global by Indication (2021-2030)
• Figure 6: Anti-Infective Drugs Market Analysis in Global by Route of Administration (2021-2030)
• Figure 7: Anti-Infective Drugs Market Analysis in Global by Distribution Channel (2021-2030)
• Figure 8: Anti-Infective Drugs Market Analysis in Global by Geography (2021-2030)
• Figure 9: Anti-Infective Drugs Market Analysis in North America (2021-2030)
• Figure 10: Anti-Infective Drugs Market Analysis in North America by Country (2021-2030)
• Figure 11: Anti-Infective Drugs Market Analysis in the US (2021-2030)
• Figure 12: Anti-Infective Drugs Market Analysis in Canada (2021-2030)
• Figure 13: Anti-Infective Drugs Market Analysis in Mexico (2021-2030)
• Figure 14: Anti-Infective Drugs Market Analysis in Europe (2021-2030)
• Figure 15: Anti-Infective Drugs Market Analysis in Europe by Country (2021-2030)
• Figure 16: Anti-Infective Drugs Market Analysis in France (2021-2030)
• Figure 17: Anti-Infective Drugs Market Analysis in Germany (2021-2030)
• Figure 18: Anti-Infective Drugs Market Analysis in the UK (2021-2030)
• Figure 19: Anti-Infective Drugs Market Analysis in Italy (2021-2030)
• Figure 20: Anti-Infective Drugs Market Analysis in Spain (2021-2030)
• Figure 21: Anti-Infective Drugs Market Analysis in the Rest of Europe (2021-2030)
• Figure 22: Anti-Infective Drugs Market Analysis in Asia-Pacific (2021-2030)
• Figure 23: Anti-Infective Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 24: Anti-Infective Drugs Market Analysis in China (2021-2030)
• Figure 25: Anti-Infective Drugs Market Analysis in Japan (2021-2030)
• Figure 26: Anti-Infective Drugs Market Analysis in India (2021-2030)
• Figure 27: Anti-Infective Drugs Market Analysis in Australia (2021-2030)
• Figure 28: Anti-Infective Drugs Market Analysis in South Korea (2021-2030)
• Figure 29: Anti-Infective Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 30: Anti-Infective Drugs Market Analysis in the Rest of the World (2021-2030)
• Figure 31: Anti-Infective Drugs Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 32: Anti-Infective Drugs Market Analysis in the Middle East (2021-2030)
• Figure 33: Anti-Infective Drugs Market Analysis in Africa (2021-2030)
• Figure 34: Anti-Infective Drugs Market Analysis in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Market Opportunities
• Figure 38: PORTER's Five Force Analysis

Anti-Infective Drugs Market By Type (Antibiotics, Antivirals, Antifungals, And Others), By Indication (Hiv Infection, Pneumonia, Respiratory Viral Infection, Sepsis, And Others), By Route Of Administration (Oral, Parenteral, And Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, And E-Commerce), And By Geography Is Expected To Advance At A Respectable Cagr Forecast till 2030 Owing To The Increasing Prevalence Of Various Targeted Diseases Such As Hospital-Acquired Infections, Sexually Transmitted Diseases, Respiratory Infections, And Others And The Increasing Research & Developmental Activities Concerning To The Anti-Infective Drugs Across The Globe

The global anti-infective drugs market was valued at USD 136.87 billion, growing at a CAGR of 4.38% during the forecast period from 2024 to 2030 to reach USD 175.94 billion by 2030. The anti-infective drugs market is observing substantial market growth due to the increasing prevalence of HIV, sepsis, tuberculosis, hospital-acquired infections, sexually transmitted diseases, and other infectious and targeted diseases across the globe. Further, the growing initiatives for the awareness of infectious diseases and the increasing geriatric population base prone to targeted and infectious diseases will also aid in increasing the demand for anti-infective drugs. Additionally, the rising advancements such as incorporation of organ-on-chip technology in order to recreate the natural physiology and mechanical forces that cells experience in the human body, which will ultimately improves the efficiency of the drugs, will in turn spur the market for anti-infective drugs. Likewise, the increasing research & developmental activities along with the surging drug approvals and launches, and other factors will create a requisite for anti-infective drugs in the market. Therefore, the market for anti-infective drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Anti-Infective Drugs Market Dynamics:

As per the data provided by World Health Organization (WHO) 2022, in 2022, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide, which accounts for six million men, 3.4 million women, and 1.2 million children. The increasing prevalence of various infectious diseases will lead to an increased demand for anti-infective drugs during the forecast period from 2022 - 2028.

Furthermore, the number of multidrug-resistant organisms has increased significantly in several parts of the world, emphasizing the importance of anti-infective agent innovation. Several institutes have launched initiatives or campaigns to raise public awareness about infectious diseases. For example, the WHO held World Antimicrobial Awareness Week (WAAW) in November 2022 with the theme 'Spread Awareness, Stop Resistance' to raise awareness about antimicrobial resistance, and its cure.

Additionally, the increasing drugs launch and approvals will also propel the demand for anti-infective drugs in the market. For instance, in May 2022, Gilead Sciences, Inc., announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company's Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP).

Also, in July 2022, Roche announced in Japan that the Ministry of Health, Labor, and Welfare had approved Ronapreve (casirivimab and imdevimab), an anti-infective drug for the treatment of patients with mild to moderate COVID-19 via intravenous infusion.

Therefore, the factors stated above collectively will drive the overall anti-infective drugs market throughout the forecast period from 2024-2030.

However, the emergence of anti-infective drug resistance, side effects associated with the anti-infective drug, and stringent regulatory approval may prove to be challenging factors for anti-infective drug market growth.

The anti-infective drugs market was positively impacted during the period of COVID- 19 pandemic as they were used to prevent the spread of the SARS-CoV-2 virus, along with other infectious agents. Although during the initial stage of the lockdown, the market suffered a downfall owing to the strict lockdown restrictions and disruption in manufacturing, and supply chains. However, as the demand for anti-infective drugs upsurges the key players in the market accelerated their manufacturing. Many key players indulged in strategic decisions, investments, and research & developmental activities concerning anti-infective drugs, leading to an increased demand for anti-infective drugs. Moreover, in October 2020, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older for the treatment of COVID-19 requiring hospitalization. Henceforth, the wide use of anti-infective drugs for the prevention of the spread of COVID-19 among the population significantly contributed to the positive growth of the anti-infective drugs market.

Anti-Infective Drugs Market Segment Analysis:

Anti-Infective Drugs Market by Type (Antibiotics, Antivirals, Antifungals, and Others), Indication (HIV Infection, Pneumonia, Respiratory Viral Infection, Sepsis, and Others), Route of Administration (Oral, Parenteral, and Topical), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the type segment of the anti-infective drugs market, the antivirals segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the rising demand and availability of antivirals drugs in the market owing to the increasing prevalence of various viral diseases, expanding launches and strategic investments and other activities relating to antiviral drugs by key players in the market, and wide application and advantages offered by the segment.

Antiviral drugs can lessen the symptoms efficiently. They also may reduce the risk of complications such as ear infections in children, respiratory complications requiring antibiotics, and hospitalization in adults.

Moreover, for people at higher risk of serious viral infection complications, early treatment with an antiviral drug can lead to milder illness instead of more severe illness that might require a hospital stay. Also, for adults hospitalized with flu and other viral illness, early antiviral treatment can reduce their risk of death and other complications.

Additionally, anti-viral drugs are utilized to treat various chronic conditions due to their effectiveness and increase in life expectancy.

Furthermore, various activities by the key players such as acquisitions, agreements or partnerships, and launches, will increase the demand for antiviral drugs in the upcoming years. For instance, in December 2022, Cipla announced that the company has been granted Emergency Use Authorisation (EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir, an antiviral drugs, in India.

Also, in November 2022, Pfizer Inc. announced an agreement with the United States government to supply 10 million treatment courses for its investigational COVID-19 oral antiviral candidate, PAXLOVID. The company had also entered into several advance purchase agreements with various other countries and had initiated bilateral outreach to approximately 100 countries around the world.

Therefore, owing to the above-mentioned factors, the demand for anti-viral drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global anti-infective drugs market during the forecast period.

North America is expected to dominate the overall Anti-Infective Drugs Market:

Among all the regions, North America is expected to dominate the global anti-infective drugs in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for anti-infective drugs in the region owing to the increasing prevalence of many infectious and targeted diseases, the increasing geriatric patient pool suffering from infectious and targeted diseases, the growing initiatives for the awareness of infectious diseases, the launch of new drugs, and the presence of key market players in the region driving the anti-infective drugs market in North America.

For instance, according to the latest estimates from the Centers for Disease Control and Prevention (CDC), approximately 34,800 new HIV infections occurred in the United States in 2019. Also, at year-end 2019, an estimated 1.2 million people in the United States aged 13 and older had HIV in the United States. Thus, the increasing prevalence of HIV infection in the United States will increase the demand for many anti-infective drugs.

Further, the United States CDC promotes the use of antivirals for various infectious diseases. For instance, in September 2022, the CDC published a brochure supporting the use of antiviral drugs for the treatment of influenza. The CDC suggested the use of four drugs approved by the FDA, oseltamivir phosphate, zanamivir, peramivir, and baloxavir marboxil. Thus, such activities by governmental health organizations promoting the use of antivirals in the nation are expected to propel the growth of the anti-infective drugs market during the forecast period.

Moreover, the anti-infective drugs launches, regulatory approvals, and other activities such as acquisitions, and agreements, in the region will lead to its increased demand in the market. For instance, in January 2022, Alembic Pharmaceuticals received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets. Doxycycline Hyclate Delayed-Release Tablets are indicated to reduce the development of drug-resistant bacteria.

Also, in May 2022, the FDA approved VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK manufactured by Phathom Pharmaceuticals, Inc., the United States based Biopharmaceutical Company focused on developing and commercializing novel treatments for gastrointestinal diseases.

Moreover, the presence of sophisticated healthcare infrastructure and high awareness among end-users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Also, the high purchasing power for expensive drugs and the presence of favorable reimbursement policies are anticipated to further fuel North America's anti-infective drugs market during the forecast period (2022 - 2028).

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the anti-infective drugs market.

Anti-Infective Drugs Market Key Players:

Some of the key market players operating in the anti-infective drugs market include Merck & Co., Inc., Gilead Sciences, Inc., GSK plc., Pfizer Inc., Alembic Pharmaceuticals, Mankind Pharma, Novartis AG, Abbott., Astellas Pharma d.o.o., Bayer AG, Bristol-Myers Squibb Company, Sanofi, Janssen Global Services, LLC, F. Hoffmann-La Roche Ltd, Cipla Inc., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Xellia Pharmaceuticals, AbbVie Inc., Melinta Therapeutics LLC, PACIFIC INDIA PHARMA LIMITED, and others.

Recent Developmental Activities in the Anti-Infective Drugs Market:

In June 2022, Merck announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for VAXNEUVANCE(TM), a Pneumococcal 15-valent Conjugate Vaccine, to include children 6 weeks through 17 years of age. It is now indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes.

In April 2022, Sandoz, a Novartis Division, announced the extension of its collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).

In August 2022, Xellia Pharmaceuticals, a pharmaceutical manufacturer specializing in anti-infective treatments, opened its manufacturing site in Cleveland, Ohio in the United States.

Key Takeaways from the Anti-Infective Drugs Market Report Study

• Market size analysis for current anti-infective drugs market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the anti-infective drugs market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global anti-infective drugs market.
• Various opportunities available for the other competitor in the anti-infective drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current anti-infective drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for anti-infective drugs market growth in the coming future?

Target Audience who can be benefited from this Anti-Infective Drugs Market Report Study

• Anti-infective drugs products providers
• Research organizations and consulting companies
• Anti-infective drugs -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in anti-infective drugs
• Various end users who want to know more about the anti-infective drugs market and the latest developments in the anti-infective drugs market.

Frequently Asked Questions for the Anti-Infective Drugs Market:

1. What are anti-infective drugs?

The anti-infective drugs are a type of therapy that is used to treat infections caused by a variety of agents. In another word, anti-infective medications are used to kill or prevent infection-causing organisms from infecting the host through replication or by releasing a range of toxins into the host. Bacteria, viruses, fungi, viruses, and microparasites are examples of infection-causing microorganisms.

2. What is the global market for anti-infective drugs?

The global anti-infective drugs market was valued at USD 136.87 billion, growing at a CAGR of 4.38% during the forecast period from 2024 to 2030 to reach USD 175.94 billion by 2030.

3. What are the drivers for the global anti-infective drugs market?

The anti-infective drugs market is witnessing positive market growth owing to the factors such as the growing prevalence of various infections, bacterial diseases, and targeted diseases across the globe, growing initiatives for the awareness of infectious diseases and their treatment, increasing geriatric population base, rising advancements such as bone marrow and organ-on-chip technologies pertaining to the anti-infective drugs, increasing new drug launches and approvals, presence of key players in the market, and others will create an exigency for the anti-infective drugs market.

4. Who are the key players operating in the global anti-infective drugs market?

Some of the key market players operating in the anti-infective drugs market includes Merck & Co., Inc., Gilead Sciences, Inc., GSK plc., Pfizer Inc., Alembic Pharmaceuticals, Mankind Pharma, Novartis AG, Abbott., Astellas Pharma d.o.o., Bayer AG, Bristol-Myers Squibb Company, Sanofi, Janssen Global Services, LLC, F. Hoffmann-La Roche Ltd, Cipla Inc., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Xellia Pharmaceuticals, AbbVie Inc., Melinta Therapeutics LLC, PACIFIC INDIA PHARMA LIMITED, and others.

5. Which region has the highest share for the anti-infective drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the global anti-infective drugs market. This can be ascribed to the increasing demand of anti-infective drugs among the patients in the region owing to increasing prevalence of HIV, sepsis, tuberculosis, hospital acquired infections, and other infective diseases. Further, the growing initiatives for the awareness of infectious diseases, increasing geriatric population base, and the presence of key domicile players in the region are the reasons which acts as a supportive factor for the North America anti-infective drugs market growth.

Table of Contents

1.Anti-Infective Drugs Market Report Introduction

2.Anti-Infective Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Anti-Infective Drugs Market Key Factors Analysis

• 4.1. Anti-Infective Drugs Market Drivers
  • 4.1.1. Growing prevalence of various infection, bacterial diseases, and targeted diseases across the globe
  • 4.1.2. Growing Initiatives for the awareness of infectious diseases
  • 4.1.3. Increasing geriatric population base
  • 4.1.4. Rising advancements such as bone marrow and organ-on-chip technologies pertaining to the anti-infective drugs
• 4.2. Anti-Infective Drugs Market Restraints and Challenges
  • 4.2.1. Emergence of anti-infective drugs resistance
  • 4.2.2. Side effects associated with anti-infective drug
• 4.3. Anti-Infective Drugs Market Opportunities
  • 4.3.1. Availability of reimbursements for infection treatment in various countries
  • 4.3.2. Increasing investments on R&D Activities of anti-infective drugs

5. Anti-Infective Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Anti-Infective Drugs Market

7. Anti-Infective Drugs Market Layout

• 7.1. By Type
  • 7.1.1. Antibiotics
  • 7.1.2. Antivirals
  • 7.1.3. Antifungals
  • 7.1.4. Others
• 7.2. By Indication
  • 7.2.1. HIV Infection
  • 7.2.2. Pneumonia
  • 7.2.3. Respiratory Viral Infection
  • 7.2.4. Sepsis
  • 7.2.5. Others
• 7.3. By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Topical
• 7.4. By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. E-commerce
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.1.2. Canada Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.1.3. Mexico Anti-Infective Drugs Market in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.2.2. Germany Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.2.4. Italy Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.2.5. Spain Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Anti-Infective Drugs Market in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.3.2. Japan Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.3.3. India Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.3.4. Australia Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.3.5. South Korea Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia Pacific Anti-Infective Drugs Market in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.4.2. Africa Anti-Infective Drugs Market in USD million (2021-2030)
    • 7.5.4.3. South America Anti-Infective Drugs Market in USD million (2021-2030)

8. Anti-Infective Drugs Market Company and Product Profiles

• 8.1. Merck & Co., Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Gilead Sciences, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. GSK plc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Pfizer Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Alembic Pharmaceuticals
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Mankind Pharma
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Novartis AG
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Abbott.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Astellas Pharma d.o.o.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Bayer AG
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Bristol-Myers Squibb Company
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Sanofi
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Janssen Global Services, LLC
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. F. Hoffmann-La Roche Ltd
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Cipla Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Xellia Pharmaceuticals
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. AbbVie Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Melinta Therapeutics LLC
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. PACIFIC INDIA PHARMA LIMITED
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us